Aarti Industries Q3 FY26 earnings call: Revenue & Margins
Q3 FY26 earnings call: what management said on revenue, margins and capex.
- Revenue
- ₹2,318Cr
- +25.8% YoY
- +10.4% QoQ
- Net profit
- ₹133Cr
- +189.1% YoY
- +25.5% QoQ
- Margin
- 14%
- +1 pp YoY
- 0 pp QoQ
Guidance rank: #21 of 70 in Chemicals & Petrochemicals
See the sector's top 10 — free with your mobile number.
The short version
The company anticipates consistent growth driven by a robust strategy navigating macro challenges. Aarti Industries expects sustainable growth supported by portfolio quality, value chain integration, and disciplined capital allocation.
From Aarti Industries Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- The company anticipates consistent growth driven by a robust strategy navigating macro challenges.
- Agrochemical volumes are stable with potential to grow from 17-18% to around 20% of the overall top line, especially post commissioning of Zone 4.
- MMA volumes have tripled in a year, expected to constitute 30-40% of the portfolio in the next 2-3 years, with geographical diversification into Europe planned.
- PDCB volumes are increasing due to new customers and growing applications like EVs.
- Zone 4 commissioning in 2026 will enable flexible product manufacturing for balanced domestic and export sales.
- The recent US-India trade deal and India-EU FTA are expected to accelerate export volumes.
2 more points from Aarti Industries Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Aarti Industries Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Majority of CAPEX for Zone 4 will be completed in the current year, with only INR 300-400 crore spilling over to next year.
- Total Zone 4 CAPEX is estimated around INR 1,600 to 1,800 crore.
- FY27 CAPEX expected to be significantly lower than current year, around INR 1,000 to 1,100 crore.
- Incremental CAPEX includes MMA capacity expansions, PEDA project, and DCB debottlenecking.
- No large projects currently in the pipeline beyond Zone 4.
- Joint Venture with Superform on track for commissioning in Q1 FY27; INR 150 crore investment from each party.
- JV with RESL progressing; construction underway, commissioning expected H1 FY27.
2 more points from Aarti Industries Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Chemicals & Petrochemicals
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Aarti Industries Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points from Aarti Industries Ltd's call on order book
Create a free account to keep reading this call
Aarti Industries Ltd — Quarterly revenue & net profit
Aarti Industries Ltd Q3 FY26 results — key figures
| ₹ Cr | Q3 FY26 | Q3 FY25 | YoY | Q2 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 2,318 | 1,843 | +25.8% | 2,100 | +10.4% |
| Operating profit (EBITDA) | 321 | 231 | +39% | 291 | +10.3% |
| Operating margin | 14% | 13% | +1 pp | 14% | 0 pp |
| Profit before tax | 118 | 40 | +195% | 93 | +26.9% |
| Net profit (PAT) | 133 | 46 | +189.1% | 106 | +25.5% |
| EPS (₹) | 3.67 | 1.27 | +189% | 2.92 | +25.7% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹3.7K Cr, net profit ₹168 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Aarti Industries's management said in earlier quarters
Others in Chemicals & Petrochemicals this season
- Neochem Bio (Q3 FY26)
Revenue for Q2 FY26 (Sept’25) stood at ₹4,583.16 Lakh. Key investor presentation takeaways from Neochem Bio Solutions Ltd's Q3 FY26 investor presentation — and
- Thirumalai Chemicals (Q3 FY26)
Q3 FY26 Revenue from Operations (INR Cr):** . Key investor presentation takeaways from Thirumalai Chemicals Ltd's Q3 FY26 investor presentation — and how it ran
- IVP (Q3 FY26)
Q3 FY26 Revenue from Operations: ₹144.97 crore . Key investor presentation takeaways from IVP's Q3 FY26 investor presentation — and how it ranks against sector
- Gujarat Alkalies (Q3 FY26)
3,144.48 Crores, down from Rs. Key investor presentation takeaways from Gujarat Alkalies & Chemicals Ltd's Q3 FY26 investor presentation — and how it ranks agai
Potential multibaggers · Q2 FY27
Potential multibaggers in Chemicals & Petrochemicals
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Aarti Industries Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Aarti Industries Ltd Q3 FY26 results?
The company anticipates consistent growth driven by a robust strategy navigating macro challenges. Aarti Industries expects sustainable growth supported by portfolio quality, value chain integration, and disciplined capital allocation.
What is Aarti Industries Ltd share price analysis?
Aarti Industries Ltd currently shows a neutral. The stock trades at a P/E of 33.8 with a market cap of ₹17,627 Cr. Investors should review the full earnings analysis for detailed insights.
Is Aarti Industries Ltd planning capital expenditure?
Majority of CAPEX for Zone 4 will be completed in the current year, with only INR 300-400 crore spilling over to next year.
Keep Aarti Industries Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
